Table 2.
Comparison of short-term clinical outcomes between the two groups.
| Best overall response | Pembrolizumab (N=101) | Sintilimab (N=63) | P value |
|---|---|---|---|
| CR | 0 | 0 | |
| PR | 62 | 41 | |
| SD | 31 | 17 | |
| PD | 8 | 5 | |
| ORR% | 61.40% | 65.10% | 0.634 |
| DCR% | 92.10% | 92.10% | 0.991 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.